Key result
Single-target hepatic AGT silencing cannot fully overcome compensatory networks in primary hypertension, requiring multi-target RNAi.
Why the study?
Hypertension affects over 1.3 billion people worldwide with fewer than 20% achieving adequate BP control, and single-target AGT silencing cannot fully overcome compensatory signaling networks driving hypertension.
This review proposes a phenotype-matched framework for multi-target RNAi therapies in hypertension to overcome the limitations of single-target AGT silencing.
Single-target hepatic AGT silencing may prove insufficient in primary hypertension; leaves open phenotype-matched multi-target RNAi development pending prospective trials.
Hypertension affects over 1.3 billion people worldwide, fewer than 20% achieve adequate blood pressure (BP) control. Poor long-term BP management accelerates irreversible damage to target organs, highlighting the urgent need for novel therapeutic approaches. Small interfering RNAs (siRNAs) are synthetic oligonucleotides that harness endogenous RNA interference machinery to silence specific disease-related genes with high sequence specificity, an approach that has opened new therapeutic avenues in cardiovascular medicine by enabling durable target modulation with infrequent dosing. N-acetylgalactosamine (GalNAc)-conjugated long-acting siRNA agents address two major limitations of oral antihypertensives: poor patient daily adherence and short-lived BP reduction. However, nearly all clinical candidates are designed to silence hepatic angiotensinogen (AGT). Single-target inhibition cannot fully overcome the compensatory signaling networks that drive primary hypertension, limiting protection against progressive target-organ damage. Existing reviews have largely summarized AGT-targeted RNA interference (RNAi) therapeutics. Rather than cataloguing individual agents, we propose a phenotype-matched framework that uses disease mechanisms to guide target selection, delivery strategies, and translational development toward precision RNAi therapy for hypertension. We review current clinical progress, examine the mechanistic basis of multi-pathway blockade, and discuss emerging molecular scaffolds for dual- and multi-target siRNA therapeutics. Finally, we discuss the major barriers to clinical translation—including extrahepatic delivery, pharmacological reversibility, and safety considerations—and identify the advances required for phenotype-guided RNAi therapies to move toward precision cardiovascular medicine. We emphasize that this phenotype-matched model is intended to generate hypotheses for target prioritization and validation, and does not represent a clinically established treatment strategy.
No takes yet. Share an insight, caveat, or question.
Lan et al. (2026) conducted a review in Hypertension. Multi-target RNAi therapeutics was evaluated. Single-target hepatic AGT silencing cannot fully overcome the compensatory signaling networks of primary hypertension, necessitating the development of phenotype-matched multi-target RNAi strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: